Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Covidien

Focus on immunotherapies: special magazine from Blue Latitude Health

Blue Latitude Health have worked with four of the eight immunotherapies currently approved by the FDA, so we've pooled our expertise across the different capabilities to give you a clear...

Blue Latitude Health

- PMLiVE

Aduro pancreatic cancer vaccine trial disappoints

Immunotherapy combination fails to improve overall survival over existing treatments

Sanofi reception

Sanofi takeover bid rebuffed by Medivation

Had sought to boost its portfolio by acquiring the US cancer therapies firm

AZ and Roche fund PatientsLikeMe cancer patient outcomes study

The online patient network's cancer experience research will also involve M2Gen

Free Thinking: From promise to practice: immuno-oncology in action

Our latest Free Thinking white paper series explores what the global outlook is like for new immunotherapy products and asks key opinion leaders and payers how they’re faring both clinically...

Research Partnership

Brain cancer glioblastoma

Glioblastoma market set for ‘meteoric rise’

Sales of treatments for rare brain cancer predicted to reach $3.3bn by 2024

Free Thinking: From promise to practice: immuno-oncology in action

This white paper explores the global outlook for new immunotherapy products, referencing key opinion leaders and payers to investigate how these products are faring both clinically and financially. Immuno-oncology therapies that...

Research Partnership

- PMLiVE

AZ takes majority stake in cancer drug developer Acerta

Will pay $4bn for a 55% share in the Dutch biopharma company

- PMLiVE

FDA deems Merck KGaA and Pfizer’s avelumab a breakthrough

Could become first-in-class treatment for Merkel cell carcinoma

CAR-T cancer therapy passes milestone

Belgianbiotech Celyad's cancer immunotherapy will now be tested at higher doses

- PMLiVE

AZ and Peregrine join forces on cancer trial

Another oncology deal for the company after a recent spate of deals

- PMLiVE

Oncology directions

With increasingly expensive cancer drugs, what price should be paid for innovation?

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links